Condition: NEUROBLASTOMA, SUSCEPTIBILITY TO


rs1057519697 in ALK gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 22072639 2011 Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

PMID 21838707 2011 Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 18923523 2008 Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

PMID 18724359 2008 Identification of ALK as a major familial neuroblastoma predisposition gene.

PMID 21242967 2011 The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.

PMID 18923525 2008 Activating mutations in ALK provide a therapeutic target in neuroblastoma.

PMID 18990089 2008 High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.

PMID 2124297 1990 Valproate-induced hepatoxicity: protective effect of L-carnitine supplementation.

PMID 21575866 2011 CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

PMID 21948233 2011 ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

rs1057519918 in CASC11;MYC gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519898 in FGFR1 gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121908163 in KIF1B gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 18334619 2008 The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.

rs756091827 in MYC;CASC11 gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519919 in MYCNOS;MYCN gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs1057519933 in PIK3CA gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121918453 in PTPN11 gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs587781525 in TP53 gene and NEUROBLASTOMA, SUSCEPTIBILITY TO PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.